Drug intelligence / Profile preview

RSV(A)-Alum

Development stage: Unknown
Lead developer: BioVaxys Technology Corporation
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**RSV(A)-Alum** is an investigational prophylactic peptide vaccine against respiratory syncytial virus subgroup A. It contains a synthetic dimeric peptide representing the ectodomain of the RSV small hydrophobic glycoprotein as the antigen, co-administered with aluminum hydroxide alum adjuvant. The vaccine is designed to induce SHe-specific humoral immune responses that may support immune recognition and clearance of RSV-infected cells. It was evaluated as an alum-formulated comparator to the DepoVax-formulated DPX-RSV(A) vaccine in a completed Phase 1 randomized, observer-blinded trial in healthy adults aged 50 to 64 years.

Other names: RSV (A)-Alum

Beyond the preview

Go deeper on RSV(A)-Alum.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RSV(A)-Alum.

Explore the full profile